Dabrafenib

證據等級: L5

預測適應症: 0 個

Dabrafenib: Evidence Incomplete — Repurposing Evaluation Pending

One-Sentence Summary

Dabrafenib (DrugBank: DB08912) is a small-molecule kinase inhibitor submitted for repurposing evaluation. The current Evidence Pack (v4, 2026-04-20) contains no TxGNN predicted indications, no approved indication records, and no safety data — a complete evaluation report cannot be issued until the three blocking data gaps are resolved.

Quick Overview

Item	Content
Original Indication	Not available in current Evidence Pack
Predicted New Indication	No TxGNN predictions generated
TxGNN Prediction Score	—
Evidence Level	— (no predictions to grade)
Taiwan Market Status	✗ Not marketed (0 approvals)
Number of Authorizations	0
Recommended Decision	Hold

Why This Evaluation Cannot Proceed

The Evidence Pack records two blocking data gaps that prevent any repurposing analysis:

DG001 — TFDA Package Insert (Severity: Blocking) Warnings and contraindications could not be retrieved from the Taiwan FDA package insert. Without this, the mandatory safety pre-screen (S1) cannot be completed, and the candidate cannot advance to mechanistic review.

DG002 — Mechanism of Action (Severity: High) Despite a successful DrugBank query (result_count: 1, 2026-03-29), MOA fields were not populated in the Evidence Pack. Mechanistic plausibility — the foundation of any repurposing rationale — cannot be assessed.

No Predicted Indications The predicted_indications array is empty. Without TxGNN output, there is no candidate disease to evaluate, no evidence to summarise, and no repurposing hypothesis to support or refute.

Dabrafenib (DB08912) is a well-characterised targeted oncology agent. However, based solely on the data present in this Evidence Pack, this report cannot present a mechanistic rationale, clinical trial evidence, or literature summary for any new indication. Populating the gaps and re-running the pipeline is required before evaluation can continue.

Cytotoxicity

Dabrafenib belongs to the BRAF kinase inhibitor class of targeted antineoplastic agents (DB08912). The following reflects drug-class knowledge; formal DrugBank toxicity data was not parsed into this Evidence Pack.

Item	Content
Cytotoxicity Classification	Targeted therapy (selective BRAF kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Handle under oncology/targeted-therapy drug handling regulations

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is missing all three components required to open a repurposing evaluation — TxGNN predicted indications, original approved indications, and a parsed safety record — making it impossible to issue any recommendation beyond Hold at this stage.

To proceed, the following is needed:

Re-run TxGNN pipeline for Dabrafenib to generate predicted_indications (pipeline entry point)
Resolve DG002 — retrieve MOA from DrugBank API and populate original_moa
Resolve DG001 — download and parse TFDA package insert PDF to populate key_warnings and contraindications
Confirm original approved indications from TFDA or international regulatory filings (FDA/EMA) and populate original_indications
Regenerate Evidence Pack (v5) once all four items above are complete, then resubmit for evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.